Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Clunie, G.
Right arrow Articles by Watts, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clunie, G.
Right arrow Articles by Watts, R.
Related Collections
Right arrow Rheumatoid Arthritis
Right arrow Health Economics
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 600-601
© 2003 British Society for Rheumatology

Letters to the Editor

Dose reduction of etanercept—can we treat more patients using a fixed budget?

G. Clunie, S. Voules and R. Watts

Department of Rheumatology, The Ipswich Hospital NHS Trust, Heath Road, Ipswich, Suffolk IP4 5PD, UK

The first 10% of the full text of this article appears below.

SIR, Tumour necrosis factor-{alpha} (TNF-{alpha}) blocking drugs (etanercept and infliximab) are effective therapies for rheumatoid arthritis [1, 2]. The introduction of these drugs into routine clinical practice has resulted in considerable pressure on drug budgets and consequent restriction of drug usage. Calculated over 5 yr, the average annual cost of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?